---
title: 'Managing side effects: guidance for use of immunotherapies in multiple myeloma'
date: '2023-12-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38066898/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20231209170651&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Chimeric antigen receptor T-cell therapy and bispecific T-cell recruiting
  antibodies have transformed the treatment landscape for relapsed/refractory multiple
  myeloma, with B-cell maturation antigen being the most common target and other targets
  in clinical development. However, these therapies are associated with unique and
  severe toxicities, including cytokine release syndrome (CRS), immune effector cell-associated
  neurotoxicity syndrome (ICANS), delayed neurotoxicity, cytopenias, ...
disable_comments: true
---
Chimeric antigen receptor T-cell therapy and bispecific T-cell recruiting antibodies have transformed the treatment landscape for relapsed/refractory multiple myeloma, with B-cell maturation antigen being the most common target and other targets in clinical development. However, these therapies are associated with unique and severe toxicities, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), delayed neurotoxicity, cytopenias, ...